NCT00278304已完成2 期
A Pilot Study of MR-Guided High Dose Rate Brachytherapy With MR Image Acquisition for Patients With Cervical Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Feasibility
研究概览
简要总结
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving external-beam radiation together with internal radiation works in treating patients with cervical cancer.
详细描述
OBJECTIVES:
Primary
- Determine the feasibility of magnetic resonance-guided, endocavitary, high-dose rate brachytherapy implants in patients with stage IB-IVB cervical cancer.
- Provide more reliable dose-volume estimations based on three-dimensional imaging-based treatment planning in patients treated with this regimen.
Secondary
- Determine the toxic effects and treatment tolerance in patients treated with this regimen.
- Correlate three-dimensional dose-volume histograms of organs at risk with treatment toxicity in patients treated with this regimen.
- Determine the disease status, time and patterns of relapse, and survival of patients treated with this regimen.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed carcinoma of the cervix of 1 of the following cellular subtypes:
- •Squamous cell
- •Adenocarcinoma
- •Adenosquamous cell
- •Stages IB-IVA disease
- •Stage IVB disease allowed provided the impact on the quality of life is tremendous (e.g., "frozen pelvis" or massive pelvic disease and fistula formation, severe pain, or bleeding)
- •Measurable and/or evaluable disease on MRI
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-2
- •No physical or physiological capacity that would preclude study treatment
- •No cognitively impaired patients who cannot provide informed consent
- •Not pregnant or nursing
- •Negative pregnancy test
- •No contraindication to MRI, including any of the following:
- •Weight > 136 kg
- •Allergy to MR contrast agent
- •Pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic devices
- •No significant unrelated systemic illness
- •No serious infections
- •No significant cardiac, pulmonary, hepatic, or other organ dysfunction that would preclude study treatment
- •Must be medically fit to receive anesthesia
- •PRIOR CONCURRENT THERAPY:
- •No prior definitive brachytherapy procedures
- •Ring implants or intravaginal cones for the relief of excessive bleeding allowed
- •No prior definitive surgical oncologic procedures (e.g., radical hysterectomy)
- •Concurrent chemotherapy, immunotherapy, or hormonal therapy allowed
排除标准
- 未提供
结局指标
主要结局
Feasibility
Comparison of dose-volume estimations based on 3D imaging-based treatment planning, with the traditional point dose method based on orthogonal radiographs
次要结局
- Tolerance
- Survival distributions
- Correlate three-dimensional dose-volume histograms of organs at risk with treatment toxicity
- Toxicity
- Disease status
- Time and patterns of relapse
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate CancerProstate CancerNCT00091390Radiation Therapy Oncology Group129
已完成
2 期
Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate CancerProstate CancerNCT00714753Mayo Clinic5
已完成
不适用
Internal Radiation Therapy in Treating Patients With Prostate CancerProstate CancerNCT00573833Memorial Sloan Kettering Cancer Center23
Unknown
3 期
Radiation Therapy in Treating Women Who Have Undergone Breast Conservation Surgery and Systemic Therapy for Early Breast CancerBreast CancerNCT00818051Institute of Cancer Research, United Kingdom840
已完成
1 期
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00053183National Cancer Institute (NCI)